ATE324455T1 - Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie - Google Patents

Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie

Info

Publication number
ATE324455T1
ATE324455T1 AT98945090T AT98945090T ATE324455T1 AT E324455 T1 ATE324455 T1 AT E324455T1 AT 98945090 T AT98945090 T AT 98945090T AT 98945090 T AT98945090 T AT 98945090T AT E324455 T1 ATE324455 T1 AT E324455T1
Authority
AT
Austria
Prior art keywords
mhc class
lag
vaccination
adjuvants
ligands
Prior art date
Application number
AT98945090T
Other languages
English (en)
Inventor
Frederique Triebel
Original Assignee
Roussy Inst Gustave
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Applied Research Systems filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE324455T1 publication Critical patent/ATE324455T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98945090T 1997-07-25 1998-07-23 Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie ATE324455T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97401800A EP0893507A1 (de) 1997-07-25 1997-07-25 Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs

Publications (1)

Publication Number Publication Date
ATE324455T1 true ATE324455T1 (de) 2006-05-15

Family

ID=8229825

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06008545T ATE478956T1 (de) 1997-07-25 1998-07-23 Verwendung von mhc klasse ii liganden (cd4 und lag-3) als adjuvans für impfungen und von lag-3 bei behandlung von krebs
AT98945090T ATE324455T1 (de) 1997-07-25 1998-07-23 Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06008545T ATE478956T1 (de) 1997-07-25 1998-07-23 Verwendung von mhc klasse ii liganden (cd4 und lag-3) als adjuvans für impfungen und von lag-3 bei behandlung von krebs

Country Status (19)

Country Link
US (2) US6410509B1 (de)
EP (3) EP0893507A1 (de)
JP (1) JP4723722B2 (de)
KR (1) KR100603075B1 (de)
CN (1) CN1184320C (de)
AT (2) ATE478956T1 (de)
AU (1) AU753738B2 (de)
BR (1) BR9811037A (de)
CA (2) CA2732570C (de)
DE (2) DE69841866D1 (de)
DK (1) DK1002108T3 (de)
EA (3) EA003740B1 (de)
EE (1) EE200000039A (de)
ES (1) ES2262242T3 (de)
IL (2) IL134212A0 (de)
NO (1) NO20000378L (de)
PT (1) PT1002108E (de)
UA (1) UA75322C2 (de)
WO (1) WO1999004810A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295895B1 (de) * 2001-09-19 2011-08-10 Institut Gustave Roussy An das Glu-Pro Motiv-bindende Proteine und Peptide, diese enthaltende therapeutische Zusammensetzungen und deren Anwendungen
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (de) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens
EP2044949A1 (de) * 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
JP5986576B2 (ja) 2010-11-10 2016-09-06 ラボラトリオス レティ，エセ．エレ． 新規アジュバント
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
CN103751778B (zh) * 2014-01-28 2016-09-28 复旦大学 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US10537626B2 (en) 2014-10-07 2020-01-21 Cytlimic Inc. HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
JP6898225B2 (ja) 2015-03-09 2021-07-07 サイトリミック株式会社 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3797794A1 (de) * 2015-04-07 2021-03-31 Cytlimic Inc. Medizin enthaltend einen toll like rezeptor 3 agonisten und ein lag-3 protein
EP3294324A1 (de) 2015-05-13 2018-03-21 Agenus Inc. Impfstoffe zur behandlung und prävention von krebs
EP3744340A3 (de) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
EP3349790A1 (de) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Langkettiges inulin zur stimulierung einer immunantwort
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
US20230057310A1 (en) * 2018-09-27 2023-02-23 Genocea Biosciences, Inc. Treatment methods
JP2020138940A (ja) 2019-02-28 2020-09-03 テルモ株式会社 治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
WO1990001870A1 (en) * 1988-08-22 1990-03-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Retroviral vectors expressing soluble cd4; a gene therapy for aids
JPH02231083A (ja) * 1988-08-31 1990-09-13 Eisai Co Ltd 組換ナチュラルキラー細胞活性化因子
IL93599A0 (en) * 1989-03-03 1990-12-23 Microgenesys Inc Kit and/or composition for the prevention or treatment of aids
EP0394827A1 (de) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
SE510135C2 (sv) * 1994-05-05 1999-04-19 Berol Nobel Ab Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
CA2194488A1 (en) * 1994-08-05 1996-02-15 Tod Paul Holler Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
PL320610A1 (en) * 1994-12-07 1997-10-13 Hoffmann La Roche Fragments of monoclonal antibodies of immunosuppressive activity
JPH10511652A (ja) * 1994-12-23 1998-11-10 ラボラトワール・オン・ソシエテ・アノニム 炎症性疾患の予防および／または治療に対するｍｈｃ−ｉｉ結合および／またはｍｈｃ−ｉｉ模倣分子の使用
ES2191784T3 (es) * 1995-12-28 2003-09-16 Univ Johns Hopkins Med Vacunas de tumores de citocinas paracrinas alogenicas.

Also Published As

Publication number Publication date
EA005405B1 (ru) 2005-02-24
EA200000161A1 (ru) 2000-10-30
EP0893507A1 (de) 1999-01-27
KR20010021706A (ko) 2001-03-15
KR100603075B1 (ko) 2006-07-20
WO1999004810A2 (en) 1999-02-04
JP4723722B2 (ja) 2011-07-13
EA003740B1 (ru) 2003-08-28
DE69834330D1 (de) 2006-06-01
ATE478956T1 (de) 2010-09-15
DK1002108T3 (da) 2006-08-21
CA2293805A1 (en) 1999-02-04
WO1999004810A3 (en) 1999-07-08
EP1002108A2 (de) 2000-05-24
EP1698701A1 (de) 2006-09-06
IL134212A (en) 2012-03-29
EP1002108B1 (de) 2006-04-26
US6410509B1 (en) 2002-06-25
CA2732570C (en) 2014-11-18
AU9254798A (en) 1999-02-16
CN1265149A (zh) 2000-08-30
BR9811037A (pt) 2000-08-01
PT1002108E (pt) 2006-09-29
EP1698701B1 (de) 2010-08-25
EA200300092A1 (ru) 2003-06-26
UA75322C2 (en) 2006-04-17
HK1030014A1 (en) 2001-04-20
DE69841866D1 (de) 2010-10-07
CN1184320C (zh) 2005-01-12
NO20000378D0 (no) 2000-01-25
EE200000039A (et) 2000-10-16
IL134212A0 (en) 2001-04-30
EA200200565A1 (ru) 2002-10-31
AU753738B2 (en) 2002-10-24
US20020192195A1 (en) 2002-12-19
NO20000378L (no) 2000-01-25
JP2001510806A (ja) 2001-08-07
CA2732570A1 (en) 1999-02-04
CA2293805C (en) 2011-05-03
DE69834330T2 (de) 2007-03-29
ES2262242T3 (es) 2006-11-16
US7109026B2 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
DE69834330D1 (de) Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie
PL366575A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka jajnika
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
TR200202231T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
NO983999L (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
DE69521521D1 (de) Mono- oder polyfunktionelle konjugate von polylysine
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
WO2002072013A8 (en) Method of treating malignancies through induction of blood immune responses
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
ATE286914T1 (de) Verwendung von blockierenden anti-tsh-rezeptor- antikörpern bei der therapie von hyperthyreosen sowie monoklonale antikörper für eine solche verwendung
PT979093E (pt) Agente viral terapeutico que interrompe o desenvolvimento de tumores
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
DE50305753D1 (de) Verfahren und mittel zur prävention, hemmung und therapie von krebserkrankungen
DK0788355T3 (da) Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme
WO1999050289A3 (en) Transformation progression-related genes and their use
WO2003034069A3 (en) Tcmp 03 protein for use in cancer therapy
ATE89727T1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1002108

Country of ref document: EP

EEIH Change in the person of patent owner